» Articles » PMID: 37014700

Long Noncoding RNA HITT Coordinates with RGS2 to Inhibit PD-L1 Translation in T Cell Immunity

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2023 Apr 4
PMID 37014700
Authors
Affiliations
Soon will be listed here.
Abstract

Programmed cell death ligand 1 (PD-L1) is an immune checkpoint protein frequently expressed in human cancers that contributes to immune evasion through its binding to PD-1 on activated T cells. Unveiling the mechanisms underlying PD-L1 expression is essential for understanding the impact of the immunosuppressive microenvironment and is also crucial for the purpose of reboosting antitumor immunity. However, how PD-L1 is regulated, particularly at translational levels, remains largely unknown. Here, we discovered that a long noncoding RNA (lncRNA), HIF-1α inhibitor at translation level (HITT), was transactivated by E2F transcription factor 1 (E2F1) under IFN-γ stimulation. It coordinated with regulator of G protein signaling 2 (RGS2) in binding to the 5' UTR of PD-L1, resulting in reduced PD-L1 translation. HITT expression enhanced T cell-mediated cytotoxicity both in vitro and in vivo in a PD-L1-dependent manner. The clinical correlation between HITT/PD-L1 and RGS2/PD-L1 expression was also detected in breast cancer tissues. Together, these findings demonstrate the role of HITT in antitumor T cell immunity, highlighting activation of HITT as a potential therapeutic strategy for enhancing cancer immunotherapy.

Citing Articles

Weighted Gene Coexpression Network Analysis Identifies Neutrophil-Related Molecular Subtypes and Their Clinical Significance in Gastric Cancer.

Chen C, Shao Y, Ye C, Yu X, Hu M, Yan J Cancer Manag Res. 2025; 17:397-418.

PMID: 40040634 PMC: 11878151. DOI: 10.2147/CMAR.S500215.


Multimodal data fusion AI model uncovers tumor microenvironment immunotyping heterogeneity and enhanced risk stratification of breast cancer.

Yu Y, Cai G, Lin R, Wang Z, Chen Y, Tan Y MedComm (2020). 2024; 5(12):e70023.

PMID: 39669975 PMC: 11635117. DOI: 10.1002/mco2.70023.


Dimethyl fumarate and extracorporeal photopheresis combination-therapy synergize in inducing specific cell death and long-term remission in cutaneous T cell lymphoma.

Sener O, Melchers S, Tengler L, Beltzig P, Albrecht J, Tumen D Leukemia. 2024; 39(2):438-450.

PMID: 39580583 PMC: 11794131. DOI: 10.1038/s41375-024-02479-1.


Potential therapies for non-coding RNAs in breast cancer.

Li R, Ji Y, Ye R, Tang G, Wang W, Chen C Front Oncol. 2024; 14:1452666.

PMID: 39372872 PMC: 11449682. DOI: 10.3389/fonc.2024.1452666.


Exploring the promise of regulator of G Protein Signaling 20: insights into potential mechanisms and prospects across solid cancers and hematological malignancies.

Wang Y, Qin J, Sharma A, Dakal T, Wang J, Pan T Cancer Cell Int. 2024; 24(1):305.

PMID: 39227952 PMC: 11373255. DOI: 10.1186/s12935-024-03487-y.


References
1.
Cacan E . Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 2017; 29(3):173-178. DOI: 10.1080/1120009X.2016.1277007. View

2.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

3.
Palucka A, Coussens L . The Basis of Oncoimmunology. Cell. 2016; 164(6):1233-1247. PMC: 4788788. DOI: 10.1016/j.cell.2016.01.049. View

4.
Lim S, Li C, Xia W, Cha J, Chan L, Wu Y . Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016; 30(6):925-939. PMC: 5171205. DOI: 10.1016/j.ccell.2016.10.010. View

5.
Li C, Lim S, Xia W, Lee H, Chan L, Kuo C . Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016; 7:12632. PMC: 5013604. DOI: 10.1038/ncomms12632. View